ALDX
Aldeyra Therapeutics, Inc.Company Information
- Company Name
- Aldeyra Therapeutics, Inc.
- CIK
- CIK0001341235
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ALDX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ALDX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-06-03
- Last sale
- 2025-08-11
- Shares purchased (TTM)
- 327,500
- Shares sold (TTM)
- 22,073
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 34,914,788
- Shares outstanding
- 60,321,068
- Ownership
- 57.88%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -6.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Available For Sale Securities Debt Securities Current | - | - | 0 | 16 | 41 | 40 | 47 | 45 | 49 | 31 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 4 | 5 | 8 | 5 | 4 | ||||||
| Assets Current | 47 | 66 | 72 | 77 | 85 | 93 | 104 | 117 | 126 | 141 | 148 | 147 | ||||||
| Deferred Costs | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 0 | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Assets | 48 | 66 | 72 | 78 | 85 | 93 | 105 | 117 | 126 | 141 | 148 | 147 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Accrued Liabilities Current | 3 | 3 | 6 | 7 | 7 | 8 | 12 | 10 | 6 | 6 | 6 | 8 | ||||||
| Long Term Debt Current | 0 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 15 | 15 | 15 | 13 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Deferred Revenue Current | - | - | 6 | - | - | - | 6 | 6 | 6 | - | 0 | - | ||||||
| Long Term Debt Noncurrent | - | 0 | 0 | 0 | 0 | 15 | 15 | 15 | - | 0 | 0 | 3 | ||||||
| Deferred Long Term Liability Charges | 6 | 6 | - | 6 | 6 | 6 | 0 | 0 | 0 | 6 | 6 | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Current | 10 | 24 | 28 | 28 | 30 | 14 | 19 | 17 | 28 | 22 | 22 | 22 | ||||||
| Liabilities | 10 | 24 | 28 | 29 | 30 | 30 | 34 | 32 | 28 | 28 | 29 | 24 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 531 | 530 | 528 | 527 | 525 | 524 | 521 | 519 | 517 | 516 | 514 | 512 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -493 | -487 | -484 | -477 | -470 | -460 | -450 | -434 | -419 | -402 | -394 | -390 | ||||||
| Stockholders Equity | 38 | 42 | 44 | 49 | 55 | 64 | 71 | 85 | 98 | 113 | 120 | 123 | ||||||
| Liabilities And Stockholders Equity | 48 | 66 | 72 | 78 | 85 | 93 | 105 | 117 | 126 | 141 | 148 | 147 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 59 | 59 | 59 | 59 | ||||||
| Shares Outstanding | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 59 | 59 | 59 | 59 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAldeyra Therapeutics, Inc. (ALDX) — SEC Financial Statements & Analysis
Aldeyra Therapeutics, Inc. (ALDX) is a pharmaceutical preparations company, incorporated in DE. Aldeyra Therapeutics, Inc. trades on Nasdaq as: ALDX. Aldeyra Therapeutics, Inc. (ALDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Aldeyra Therapeutics, Inc. carries a market cap of $128.48M, a P/E ratio of -5.57x, a P/B ratio of 3.39x, an enterprise value of $83.39M, and an EV/EBITDA multiple of -3.50x. On profitability, it posts a Return on Equity (ROE) of -49.48%, a Return on Assets (ROA) of -34.80%, and a Return on Invested Capital (ROIC) of -241.84%. Per share, it reports EPS of $-0.38, diluted EPS of $-0.38, free cash flow per share of $-0.37, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -54.46% year-over-year and EPS growth of -54.67% year-over-year. On the balance sheet, it maintains a current ratio of 4.91x, a quick ratio of 4.67x, working capital of $37.72M, a debt-to-equity ratio of 0.25x, a debt ratio of 0.2, an interest coverage ratio of -16.95x, free cash flow of $-22.02M (TTM), and net debt of $-45.09M. Figures sourced from SEC EDGAR.
- Market Cap
- $128.48M
- P/E TTM
- -5.57x
- EPS TTM
- $-0.38
- P/B TTM
- 3.39x
- ROE TTM
- -49.48%
- ROA TTM
- -34.80%
- Debt To Equity
- 0.25x
- Free Cash Flow TTM
- $-22.02M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aldeyra Therapeutics, Inc. in?
Aldeyra Therapeutics, Inc. (ALDX) operates in the Pharmaceutical Preparations industry.
What exchange does ALDX trade on?
Aldeyra Therapeutics, Inc. (ALDX) trades on the Nasdaq.
Where is Aldeyra Therapeutics, Inc. incorporated?
Aldeyra Therapeutics, Inc. is incorporated in DE.
When was Aldeyra Therapeutics, Inc. (ALDX)'s most recent SEC filing?
Aldeyra Therapeutics, Inc. (ALDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ALDX's market cap?
Aldeyra Therapeutics, Inc. (ALDX) has a market capitalization of $128.48M as of 2026-06-30.
What is ALDX's EPS (earnings per share)?
Aldeyra Therapeutics, Inc. (ALDX)'s trailing twelve month EPS is $-0.38 as of 2026-06-30.
What is ALDX's ROE (return on equity)?
Aldeyra Therapeutics, Inc. (ALDX)'s trailing twelve month Return on Equity (ROE) is -49.48% as of 2026-06-30.
What is ALDX's ROA (return on assets)?
Aldeyra Therapeutics, Inc. (ALDX)'s trailing twelve month Return on Assets (ROA) is -34.80% as of 2026-06-30.
What is ALDX's ROIC (return on invested capital)?
Aldeyra Therapeutics, Inc. (ALDX)'s trailing twelve month Return on Invested Capital (ROIC) is -241.84% as of 2025-09-30.
What is ALDX's EV/EBITDA?
Aldeyra Therapeutics, Inc. (ALDX)'s trailing twelve month EV/EBITDA is -3.50x as of 2026-06-30.